Skip to main content
editorial
. 2020 Feb 20;6(1):19–26. doi: 10.1016/S2055-6640(20)30006-6

Figure 1.

Figure 1.

(a) Plasma sCD30 in HIV-uninfected, untreated viraemic, ART-suppressed, CSF ‘escape’ and controller subgroups. (b) CSF sCD30 in HIV-uninfected, untreated viraemic, ART-suppressed, CSF ‘escape’ and controller subgroups. I indicates statistically significant comparison between group of interest and HIV-1 uninfected subgroup. II indicates statistically significant comparison between group of interest and viraemic subgroup. ART: antiretroviral therapy; CSF: cerebrospinal fluid